Albert Bourla, Pfizer CEO (Laurent Gillieron/Keystone via AP Images)
Updated: Pfizer to buy Seagen for $43B, ending long-running M&A saga for biotech
Pfizer will buy cancer drugmaker Seagen for $43 billion in one of the industry’s biggest deals in years.
The deal, for $229 a share, ends …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
